Leukemia
In this section, we cover the latest in cutting-edge leukemia news and research. Leukemias are a group of diseases that result from the unregulated clonal proliferation of cells secondary to genetic abnormalities in hematopoietic cells. Compared to normal cells, a high rate of proliferation and low rate of apoptosis offers leukemic cells a growth advantage.
Acute Lymphoblastic Leukemia
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
In a podcast, experts explore chemo-free ALL therapies, CAR T breakthroughs, and the future of T-cell–targeted treatments.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Naval Daver, MD reviews new immunotherapy and targeted strategies transforming ALL treatment and outcomes.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
Guest contributor Moaath Mustafa Ali, MD, MPH, outlines the transforming treatment paradigm of Ph+ ALL.
Acute Myeloid Leukemia
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Naval Daver, MD reviews new targeted therapies transforming AML treatment in both young and older patient groups.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
A group of experts led by Naval Daver, MD discuss mutation loss, MRD dynamics, and transplant timing in evolving AML care.
A post-hoc analysis of long-term results in the AGILE trial adds to promising initial efficacy and safety results.
Chronic Lymphocytic Leukemia
CLL treatments are advancing—hear Dr. Wierda discuss resistance, remission, and future therapies on the HemOnc Pulse.
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
AMPLIFY trial shows AVO combo achieves deep remissions in CLL patients with high-risk TP53 aberrations.
10-year RESONATE-2 results show ibrutinib delivers lasting survival benefits for CLL/SLL as first-line therapy.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Dr. Sanam Loghavi outlines genetic testing, MRD monitoring, and evolving strategies in newly diagnosed CLL.
Chronic Myeloid Leukemia
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Enrolled patients had chronic phase CML without BCR::ABL1 T315I mutation and had undergone at least two prior TKI treatments.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Expert insights from a HemOnc Pulse Live! session offer a compelling look at where CML and MPN care is headed.
How have TKIs transformed CML survival and what’s next for treatment-free remission and deeper MPN responses?
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.